Drug Profile
GDC 0310
Alternative Names: GDC-0310; RG 6029Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Developer Genentech; Xenon Pharmaceuticals
- Class Analgesics; Non-opioid analgesics; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO)
- 25 Oct 2018 GDC 0310 is still in phase I trials for Pain in USA (Genentech's pipeline, October 2018)
- 07 Nov 2017 Genentech announces that based on results from its preclinical toxicology studies GDC 0310 will not enter a phase II clinical trial in the first quarter of 2018